Arcutis Biotherapeutics, Inc.
ARQT
$22.91
$0.673.01%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 83.83% | 121.69% | 164.13% | 196.01% | 412.79% |
| Total Other Revenue | 0.00% | -- | -- | -92.86% | -- |
| Total Revenue | 81.48% | 121.69% | 164.13% | 32.84% | 427.58% |
| Cost of Revenue | 69.27% | 57.82% | 116.28% | 171.19% | 207.44% |
| Gross Profit | 82.79% | 130.65% | 170.18% | 23.11% | 471.41% |
| SG&A Expenses | 37.10% | 6.10% | 18.90% | 16.80% | 18.35% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 40.67% | 8.20% | 18.76% | 11.31% | 5.75% |
| Operating Income | 340.92% | 121.82% | 70.82% | 22.43% | 87.52% |
| Income Before Tax | 270.71% | 118.03% | 70.30% | 29.31% | 84.21% |
| Income Tax Expenses | 45.51% | -- | -- | -13.89% | 1,192.00% |
| Earnings from Continuing Operations | 261.24% | 117.84% | 69.64% | 29.17% | 83.72% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 261.24% | 117.84% | 69.64% | 29.17% | 83.72% |
| EBIT | 340.92% | 121.82% | 70.82% | 22.43% | 87.52% |
| EBITDA | 358.92% | 124.05% | 71.63% | 31.56% | 87.96% |
| EPS Basic | 256.94% | 117.38% | 70.48% | 37.60% | 87.93% |
| Normalized Basic EPS | 266.22% | 117.57% | 71.12% | 37.71% | 88.29% |
| EPS Diluted | 243.09% | 117.38% | 70.48% | 37.60% | 87.88% |
| Normalized Diluted EPS | 257.06% | 116.85% | 71.12% | 37.71% | 88.29% |
| Average Basic Shares Outstanding | 2.67% | 2.67% | 2.85% | 13.50% | 34.93% |
| Average Diluted Shares Outstanding | 8.58% | 6.90% | 2.85% | 13.50% | 34.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |